Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA564134
Title Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha.
Publication Date Jul 2012
Media Count 13p
Personal Author N. Jing
Abstract There are two signaling pathways: HIF-1alpha and Stat3 are important targets for prostate cancer (PC) therapy. HIF-1alpha is the key gene that controls the amount of the transcription of hypoxia-inducible genes. Overexpression of HIF-1alpha not only strongly enhances the rate of tumor growth and metastatic potential, but also contributes to resistance to radiotherapy and chemotherapy, leading to treatment failure and increased patient mortality. Stat3 participates in oncogenesis through the upregulation of genes encoding apoptosis inhibitors, cell-cycle regulators, and inducers of angiogenesis in many human cancers, including prostate cancer. Also, Stat3 suppresses anti-tumor immune responses and mediates the cancer-promoting properties. Previously, we demonstrated that treatment of PC in preclinical models with a combination of a Stat3 inhibitor and a HIF-1alpha inhibitor greatly enhanced drug efficacy and dramatically increased apoptosis in human tumors compared with the use of either agent alone, showing that targeting both Stat3 and HIF-1alpha together can improve tumor response. In this research period, we have developed TEL03, a dual inhibitor from nature products, for cancer therapy. TEL03 targets both HIF-1alpha and Stat3, blocks the expression of their down-regulated oncogenes and significantly suppresses tumor growth in vivo. TEL03 also demonstrated a greater-than-expected in vivo potency, perhaps because of synergy arising from the ability of this agent to simultaneously target two critical oncogenic pathways.
Keywords A dual inhibitor
Cancer therapy
Prostate cancer

Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author Baylor Coll. of Medicine, Houston, TX.
Document Type Technical report
Title Note Annual rept. 1 Jul 2011-30 Jun 2012.
NTIS Issue Number 1302
Contract Number W81XWH-10-1-0352

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader